Bio-Gene Technology Limited Overview
Bio-Gene Technology is a pre-revenue Australian agtech developer that owns two insecticidal active ingredients based on beta-triketone chemistry found in a sub-type of Eucalyptus. Flavocide (flavesone) is a synthesised, nature-identical molecule. Qcide is a steam-distilled eucalyptus oil rich in tasmanone. The company's core claim is a novel mode of action. That matters because insecticide resistance is eroding the established chemical classes in public health mosquito control, crop protection, grain storage, animal health and consumer pest control. Bio-Gene runs an asset-light, out-licensing model. It aims to own the active-ingredient registrations and manufacturing know-how, while partners (Envu, Clarke, Evergreen Garden Care, STK, and Sumitomo/Nakashima in Japan) formulate, register end products and sell. At about A$6M market capitalisation, with A$1.94M of cash at FY2026 year end and a going-concern material uncertainty, the investment case is binary. It rests on Flavocide clearing GLP toxicology and an Australian (APVMA) filing in Q2 CY2027, and on Qcide generating first commercial revenue in Japan.
Company's own description (paraphrased from FY2026 AR, "Who We Are" and Principal Activities). Bio-Gene describes itself as an Australian agtech development company. Its stated goal is to enable a new generation of insecticides that address food security and public health while dealing with insecticide resistance and toxicity. The technology rests on naturally occurring beta-triketone compounds, with applications in crop protection (including grain storage), public health, consumer and animal health. The company cites estimates that around 600 insect and arthropod types resist more than one insecticide class, and that more than 60 countries report mosquito resistance. It sizes the global insecticide market at over US$31 billion per year.
Business model (FY2026 AR). The model has four parts:
-
Develop and own active-ingredient registrations internationally, starting with an APVMA application for Flavocide as a new active constituent.
-
Develop proprietary manufacturing and production know-how. Flavocide synthesis was scaled at pilot level with Rallis India. Qcide oil comes from Bio-Gene's own Queensland plantation and distillation process.
-
Partner with established companies for formulation, product registration, marketing and distribution.
-
Earn revenue from active-ingredient supply, technology licence fees, milestone payments and royalties.
Revenue model mix (as of FY2026).
Value-chain position. Bio-Gene sits upstream, at active-ingredient discovery, development and registration. This is the same position as agrochemical majors' discovery units, but without their capital base. Manufacturing is outsourced: Flavocide toll synthesis in India, and Qcide biomass grown on a leased or managed Queensland plantation with distillation. Toxicology work goes to overseas GLP contract research organisations. Formulation and end-product commercialisation are delegated to partners.
Customer types (prospective). Professional pest management and mosquito-abatement companies (Envu, Clarke). Consumer home-and-garden brands (Evergreen Garden Care; Nakashima Trading in Japan). Crop-protection companies (STK Bio-Ag for Qcide in crop protection; earlier BASF for grain storage). Government and defence programmes (US Department of Defense Deployed Warfighter Protection; US CDC vector-control programme). Trading houses (Sumitomo Corporation).
End-markets. Public health vector control (mosquitoes, ticks). Consumer and household pest control. Professional pest management. Crop protection and organic agriculture (Qcide has OMRI listing). Grain storage. Animal health.
Independent characterisation. Bio-Gene is a micro-cap, single-segment, pre-commercial R&D company. Its economics resemble a pre-clinical biotech more than an agrochemical business. Over FY2022–FY2026 its cumulative operating cash burn was about A$12.5M, funded almost entirely by equity and the R&D tax incentive. Its main asset is a patent family around flavesone and tasmanone uses and synergies, plus one plantation-based supply chain for Qcide. The FY2026 annual report marks the shift from "discovery and evaluation" to "regulatory dossier and first commercial term sheet". Nothing is yet binding or revenue-generating.
Strategy
Stated strategy (FY2026 AR, paraphrased). Bio-Gene's strategy is to develop its proprietary technologies until they can be licensed to commercial partners for further development and market release. It would then earn revenue from active-ingredient supply, milestones and royalties. Recurring themes in the Chair and CEO letter are:
-
a novel mode of action as the differentiator against resistance;
-
nature-derived safety and sustainability positioning;
-
owning the active-ingredient registration;
-
partnering for formulation and distribution;
-
building scalable, low-cost supply.
Strategic initiatives, last 24 months (Oct 2024 – Oct 2026).
Cost programmes. No formal cost-reduction target has been announced. The asset-light outsourcing policy is the main cost discipline: no material capex is intended in the near term (FY2026 AR).
ESG commitments. None quantified. The company says its operations are not subject to significant environmental regulation.
Medium-term guidance. No financial guidance is provided. The AR says further disclosure on likely developments would unreasonably prejudice the company. The operational milestones guided for FY2027 are: Flavocide toxicity results; APVMA submission (Q2 CY2027); Asian mosquito results (Q4 CY2026); and Qcide Japan launch (late CY2026).
Products & Services
Bio-Gene has no products on sale. Its portfolio consists of two active ingredients and their targeted use patterns, often called "products" in company materials. The FY2026 annual pipeline review kept eight priority target products and use patterns. The company has not published the full list of eight, so the catalogue below is assembled from disclosed programmes.
Flavocide® (active constituent: flavesone)
| Attribute | Detail |
|---|---|
| Description | Synthetically produced, nature-identical beta-triketone (flavesone) originally found in eucalyptus leaf biomass |
| Key capability | Novel mode of action, different from all currently available insecticides per company research. Efficacy shown against resistant pest populations. Synergy with pyrethroids (permethrin, pyrethrin). |
| Manufacturing | Proprietary synthesis route owned by Bio-Gene. Pilot-scale production by Rallis India (Dahej) produced several hundred kg at consistent specification (Sep 2024). |
| Regulatory status | APVMA pre-application assistance done. GLP dossier under construction: OECD 407 (28-day) done; OECD 417 pilot done; OECD 424 and 443 in progress (preliminary reports were expected Sep 2026); OECD 408 (90-day), OECD 417 GLP and OECD 414 (rabbit developmental) still to come; 5-batch analysis and storage stability underway. First APVMA application targeted Q2 CY2027. Intended label scope: professional and domestic uses including public health mosquito control, excluding food production at first. |
| Target customers | Professional mosquito control (Envu, Clarke), consumer (Evergreen Garden Care), defence (US DoD), animal health, grain storage (historical BASF work) |
| Pricing model | Not publicly disclosed. Intended to combine active-ingredient supply margin, licence fees, milestones and royalties. |
| Launch year | None. No registered product as of Oct 2026. |
| Programme | Description | Partner(s) | Stage (latest disclosure) |
|---|---|---|---|
| Professional mosquito control | Formulations for mosquito management in professional pest-control use patterns | Envu (since Aug 2024) | Several formulations evaluated (FY2025 AR); confidential development continuing |
| Mosquito barrier spray | Residual barrier spray use pattern | Clarke Mosquito Control (US) | Formulation optimisation (H1 FY2024) |
| Wearable mosquito-protection device (spatial emanator) | Device releasing Flavocide to protect against flying vectors | US DoD DWFP grant; GearJump Technologies; US military and agricultural research institutions | Prototypes built; early small-cage trials showed mosquito mortality (FY2026 AR) |
| Tick control (acaricide) | Emulsion-in-water prototype against Ixodes scapularis | Purdue University | >90% nymph mortality in 24h, up to 4 weeks residual (lab); field validation proposed |
| Asian vector control | Testing vs Aedes aegypti, Ae. albopictus, Culex quinquefasciatus to WHO guidelines | Testing facilities in Singapore and the region (unnamed) | Initial phase completion expected Q4 CY2026 |
| Consumer home & garden | Consumer insecticide applications | Evergreen Garden Care | Ongoing (FY2025 AR) |
| Stored-grain protection | Grain protectant, alone and in combinations | BASF (historical), GRDC, Queensland DAF | Met key industry standards in grain-storage trials (historical); current status not disclosed |
| Synergistic combination products | Flavesone + permethrin or pyrethrin | Licensing opportunity | US patent to 2040; equivalents granted in AU, JP, NZ, 22 ARIPO states |
Named Flavocide programmes and use patterns
Qcide® (active constituent: tasmanone-rich eucalyptus oil)
| Attribute | Detail |
|---|---|
| Description | 100% natural, non-synthetic oil steam-distilled from leaves of a selected Eucalyptus cloeziana (Gympie Messmate) cultivar, high in tasmanone |
| Key capability | Novel mode of action. Ovicidal activity (national-phase patent filings). Botanical and organic positioning. |
| Production | Own plantation in Far North Queensland. 14th harvest Jul 2025 and 15th harvest Feb 2026 at consistent commercial specification. Biomass pre-treatment and distillation being optimised. Tree-improvement programme and seed production area established. New plantings ready for first harvest in spring 2026. |
| Regulatory / market access | OMRI Listed (Dec 2025) as a botanical pesticide under USDA NOP, with no restrictions on composition. This is not itself a product registration. Japanese import and supply approval application initiated. |
| Target customers | Japanese household nuisance-insect market (Nakashima via Sumitomo); organic agriculture and crop protection (STK); defence and indoor pests (US DoD) |
| Pricing model | Not publicly disclosed. Japan structure: Bio-Gene supplies oil and licenses IP; Sumitomo handles ordering, trade finance, logistics and import approval; Nakashima formulates, packages and sells. |
| Launch | Targeted late CY2026 in Japan (non-binding) |
| Programme | Description | Partner(s) | Stage |
|---|---|---|---|
| Japan household insecticides | Range of products containing Qcide against household nuisance insects | Sumitomo Corporation; Nakashima Trading Co. Ltd | Non-binding term sheet (Mar 2026); draft commercial terms, import approval application, prototype formulations, packaging work |
| Crop protection (global) | Qcide-based biological crop protection | STK Bio-Ag Technologies (Development & Licence Agreement, Jul 2023) | STK funds registration; current milestones not disclosed |
| Indoor residual treatment | Bed bugs, resting houseflies, indoor pests | US DoD DWFP grant; US research partners | Laboratory testing of prototypes, starting with houseflies |
| Ovicide | Egg-stage control | IP | National phase entered: AU, BR, CA, EU, IN, JP, NZ, US |
| Asian vector control | As for Flavocide | — | Results Q4 CY2026 |
Named Qcide programmes
Services
None.
Financial Narrative
Data bases. FY2025–FY2026 are taken from the audited FY2026 Annual Report. FY2022–FY2024 come from S&P Global Market Intelligence (via StockAnalysis) and are reconciled to the AR where possible. S&P's "revenue" line for FY2022–FY2024 probably captures grant or collaboration income. A second aggregator (Stoxray) reports FY2023 revenue of A$0.595M and FY2024 revenue of A$0.018M, against S&P's A$0.15M and A$0.02M. This discrepancy is flagged. The company's own Appendix 4E reports nil revenue from ordinary activities in FY2025 and FY2026.
Income statement
EPS for FY2022–FY2024 is S&P data rounded to whole cents. FY2024 weighted average shares is approximate (S&P). FY2025–FY2026 are exact per AR Note 4. FY2026 operating loss excludes A$0.025M interest income. The FY2026 gross profit line is not meaningful.
Margins and growth
Gross, operating, EBITDA and net margins are not meaningful for any year from FY2022 to FY2026. Revenue is nil or immaterial: the FY2024 operating loss of A$2.50M sat against A$0.02M of revenue, and S&P reports an FCF margin of minus 15,065%. The 5-year revenue CAGR is not meaningful because revenue fell from A$0.45M (FY2022) to nil (FY2025–FY2026). A more useful measure is net-loss CAGR, FY2022–FY2026, of about −5.5% per year. The loss narrowed from A$2.91M to A$2.33M.
Balance sheet
The FY2025 short-term "debt" is an A$51,209 insurance premium funding liability (AR Note 12). Small loan repayments of A$0.08M appear in FY2022–FY2023 financing cash flows (S&P), but no debt balance is shown. Net tangible assets per share were 0.5 cents in both FY2025 and FY2026 (Appendix 4E). Unrecognised tax losses are A$18.47M, a potential benefit of A$4.62M at 25% (FY2026 AR).
Cash flow
FY2026 operating cash flow benefited from A$0.59M of "other income" receipts (mainly grant cash) and A$0.52M of R&D tax refund, received in Nov 2025 for FY2025 spending (AR cash flow statement).
Ratios
ROIC, interest coverage, net debt/EBITDA, asset turnover and cash conversion cycle are not meaningful. Invested capital is negligible, interest expense is close to zero (A$2,559 in FY2026), EBITDA is negative, and the company holds no inventory or trade receivables.
Commentary
Trend 1: steady but modest losses. Net losses have stayed in a narrow A$2.3–3.1M band for five years, peaking in FY2023 at A$3.10M. FY2026's A$2.33M loss is the lowest in the period. It was not driven by spending cuts: total operating expenses actually rose 9.7% to A$3.41M. The improvement came from other income doubling to A$1.08M, mainly because US DoD research-grant income rose from A$0.10M to A$0.58M (AR Note 3a). In effect, US government money is now meaningfully subsidising the R&D budget.
Trend 2: spending is shifting toward regulatory R&D. R&D expense rose 28% to A$1.77M in FY2026. Within it, consulting jumped from A$0.14M to A$0.54M and studies and development rose to A$0.77M. Commercialisation salaries and management or corporate costs both fell. This mix shift matches the move into GLP toxicology. Another A$625,000 of study fees is committed for OECD 443 and 417 work, payable before the end of FY2027 (AR Note 16). IP costs rose 37% to A$0.34M as patent families entered national phase.
Trend 3: the balance sheet steps down, then is partly refilled. Cash fell from A$6.34M (FY2022) to A$1.14M (FY2025), when runway reached about 0.45 years. That forced the May–July 2025 and May–August 2026 raises. Equity has been rebuilt to A$2.09M, but at a cost. Shares on issue rose 2.4x, from 179M (FY2022) to 438M (Aug 2026), and 179M options remain outstanding. The quarterly report for Q1 FY2026 noted only about 0.98 quarters of funding before new capital arrived (InvestSMART summary, Oct 2025).
Trend 4: going concern. Both the FY2026 annual report and the H1 FY2026 half-year report disclose a material uncertainty about going concern. Directors rely on forecast capital raising and R&D tax refunds. A pro-forma cash figure combining 30 June cash (A$1.94M) and the post-balance-date tranche 2 and SPP shortfall proceeds (A$1.25M gross) is about A$3.19M before costs and before July–September burn. This is arithmetic only, not a disclosed figure. At the FY2026 burn rate, that implies runway into roughly mid-CY2027, which is about the targeted APVMA filing window. Additional capital before or around the filing looks likely.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment revenue (AUD Mn, S&P basis) | 0.02 | 0 | 0 |
Segment other income incl. R&D TI and grants (AUD Mn) | 0 | 0.52 | 1.08 |
Segment pre-tax loss (AUD Mn) | -2.41 | -2.58 | -2.33 |
Segment share of total revenue (%) | 100 | 100 | 100 |
Functional cost centre (AUD Mn)
| Functional cost centre (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Research & Development | 1.38 | 1.77 |
Commercialisation (incl. farm management) | 0.56 | 0.45 |
Intellectual Property | 0.25 | 0.34 |
Management & Corporate | 0.62 | 0.49 |
Directors | 0.19 | 0.19 |
Professional services | 0.07 | 0.13 |
Depreciation & amortisation | 0.04 | 0.04 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD Mn, S&P basis) | 0.45 | 0.15 | 0.02 | 0 | 0 |
Gross profit (AUD Mn, S&P basis) | 0.22 | -0.12 | -0.30 | -0.25 | 0 |
R&D expense (AUD Mn) | 1.90 | 1.98 | 1.07 | 1.38 | 1.77 |
Operating loss (AUD Mn) | -2.97 | -3.18 | -2.50 | -2.62 | -2.36 |
EBITDA (AUD Mn, op. loss + D&A) | -2.93 | -3.13 | -2.46 | -2.58 | -2.32 |
Pre-tax loss (AUD Mn) | -2.91 | -3.10 | -2.41 | -2.58 | -2.33 |
Net loss (AUD Mn) | -2.91 | -3.10 | -2.41 | -2.58 | -2.33 |
Basic/diluted EPS (A$ cents) | -2.0 | -2.0 | -1.0 | -1.22 | -0.75 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Weighted avg shares (M) | 179 | 178 | 190 | 185.82 | 309.11 |
Income Statement
| Metric | FY2025 | FY2026 |
|---|---|---|
R&D tax incentive (AUD Mn) | 0.39 | 0.47 |
Research grants (AUD Mn) | 0.10 | 0.58 |
Interest (AUD Mn) | 0.04 | 0.02 |
Other (AUD Mn) | 0.00 | 0 |
Total other income (AUD Mn) | 0.52 | 1.08 |
Total operating expenses (AUD Mn) | 3.11 | 3.41 |
Balance Sheet and Share Count (M)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | 7.30 | 3.84 | 3.16 | 2.15 | 2.61 |
Cash & equivalents (AUD Mn) | 6.34 | 2.99 | 2.21 | 1.14 | 1.94 |
Short-term debt (AUD Mn) | 0 | 0 | 0 | 0.05 | 0 |
Long-term debt (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Net debt (AUD Mn, negative = net cash) | -6.34 | -2.99 | -2.21 | -1.09 | -1.94 |
Total liabilities (AUD Mn) | 1.03 | 0.61 | 0.37 | 0.52 | 0.52 |
Shareholders' equity (AUD Mn) | 6.27 | 3.22 | 2.79 | 1.63 | 2.09 |
Goodwill (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Intangibles – Qcide licences (AUD Mn) | 0.28 | 0.24 | 0.20 | 0.17 | 0.13 |
Working capital (AUD Mn) | 5.99 | 3.01 | 2.59 | 1.46 | 1.96 |
Accumulated losses (AUD Mn) | -14.50 | -17.43 | -19.64 | -22.03 | -24.20 |
Shares on issue at 30 Jun (M) | 179.06 | 177.91 | 201.36 | 266.42 | 386.08 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | -1.99 | -3.28 | -2.75 | -2.54 | -1.94 |
Capex (AUD Mn, outflow) | 0.01 | 0 | 0.01 | 0 | 0 |
Free cash flow (AUD Mn) | -2.00 | -3.28 | -2.76 | -2.54 | -1.94 |
Equity issued, gross (AUD Mn) | 4.72 | 0 | 2.03 | 1.50 | 2.99 |
Share issue costs (AUD Mn) | 0.24 | 0 | 0.06 | 0.08 | 0.20 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
R&D tax incentive cash received (AUD Mn) | 0.51 | 0.45 | 0.50 | 0.54 | 0.52 |
Net change in cash (AUD Mn) | 2.41 | -3.35 | -0.78 | -1.07 | 0.80 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%, year-end equity) | -46.4 | -96.3 | -86.4 | -158.3 | -111.5 |
ROA (%, year-end assets) | -39.9 | -80.7 | -76.3 | -120.0 | -89.3 |
Current ratio (x) | 6.93 | 6.28 | 8.40 | 3.86 | 4.78 |
Debt/equity (x) | 0 | 0 | 0 | 0.03 | 0 |
Cash runway at year-end burn (years) | 3.19 | 0.91 | 0.80 | 0.45 | 1.00 |
Results by Region
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia – R&D tax incentive income (AUD Mn) | 0 | 0.39 | 0.47 |
United States – research grant income, inferred DoD (AUD Mn) | 0 | 0.10 | 0.58 |
Australia – interest income (AUD Mn) | 0.09 | 0.04 | 0.02 |
Total revenue from ordinary activities, all regions (AUD Mn) | 0.02 | 0 | 0 |
Share Price & Returns
| Reference point | Price (AUD) | Source |
|---|---|---|
8 Oct 2026 | 0.014 | StockAnalysis |
25 Sep 2026 | 0.017 | StockAnalysis |
5 Aug 2026 | 0.023 | StockAnalysis |
31 Jul 2026 (at quarterly release) | 0.018 | InvestSMART |
3 Mar 2026 (at regulatory update) | 0.033 | InvestSMART |
30 Jan 2026 | about 0.031–0.04 | InvestSMART; Motley Fool |
31 Oct 2025 | 0.023 | InvestSMART |
52-week high / low | 0.049 / 0.016 | StockAnalysis |
May 2023 (52-wk high then) | 0.13 | InvestSMART |
Nov/Dec 2017 (post-IPO) | about 0.22 | Pearler |
Share Count (M) and Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Shares on issue at 30 Jun (M) | 179.06 | 177.91 | 201.36 | 266.42 | 386.08 |
Gross equity raised (AUD Mn) | 4.72 | 0 | 2.03 | 1.50 | 2.99 |
Net tangible assets per share (A$ cents) | 3.3 | 1.7 | 1.3 | 0.5 | 0.5 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Valuation Snapshot
| Multiple | Value | Comment |
|---|---|---|
Market cap | about A$6.1M | — |
Enterprise value | about A$4.2M (using 30 Jun 2026 cash of A$1.94M; lower on a pro-forma basis including August proceeds) | Derived |
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA |
EV/Sales | n/m | Nil revenue |
P/B | about 2.9x (on FY2026 equity A$2.09M) | Derived |
Fully diluted shares | about 617M (438M + 179M options, all out of the money at 3.4–4.6c) | Derived |
Analyst Conclusions
Management guidance (FY2026 AR, operational only).
Consensus growth expectations. None. There is no broker coverage.
Bull case (grounded in the data above).
-
Regulatory de-risking is close. If OECD 424 and 443 come back clean, roughly 55% of total study duration, per the Mar 2026 update, is behind the company. A Q2 CY2027 APVMA filing would then make Flavocide a dossier-backed novel-MoA active that majors can license, valued from a A$4M enterprise value base.
-
The synergy patent is a licensing asset. US protection to 2040 for combinations with permethrin and pyrethrin lets incumbents rejuvenate pyrethroid franchises facing resistance. Envu and Clarke are already evaluating formulations.
-
First revenue and non-dilutive funding are both arriving. A Japan launch with a Sumitomo-group channel in late CY2026 would be the first product revenue. DoD grant income (A$0.58M in FY2026) already offsets about one-third of R&D spending.
Bear case.
-
Funding treadmill. A$1.94M of year-end cash against A$1.94M of annual burn, a going-concern note, and weak SPP take-up (24%) point to further discounted raises. The 179M options are well out of the money.
-
Binary toxicology risk and slipping timelines. One study is already delayed (OECD 424). The APVMA target has drifted by about one quarter. Any reproductive or neurotoxicity flag could restrict the label or end the programme.
-
Nothing binding yet. The Japan deal is a non-binding term sheet. After years of collaborations (BASF, Clarke, Evergreen, Envu, STK), revenue from ordinary activities remained nil in FY2025 and FY2026.
Key catalysts and monitorables (next 12 months).
Concluding analyst verdict.
Bio-Gene Technology is a classic micro-cap "registration option". Its scientific premise is credible, its validation partners are external and serious, and its balance sheet does not match the length of the road ahead. The positives are tangible. The company owns a patented, nature-identical active with a claimed novel mode of action and synergy protection in the US to 2040. Its industrial partners include a Tata-group manufacturer, the former Bayer Environmental Science (Envu), a Sumitomo trading-house channel in Japan, and US DoD, CDC and Purdue scientific validation. FY2026 also showed better cost discipline: the net loss fell to A$2.33M as grant income rose roughly six-fold.
Those positives do not yet translate into a self-funding business. Revenue from ordinary activities is nil. Cash at year end covered only about a year of burn. Auditors and directors flag a material going-concern uncertainty. The share count has risen 2.4x in four years, and the market has priced the equity at about A$6M, below its 52-week low, with an enterprise value of only around A$4M. That valuation implies deep scepticism that Flavocide reaches registration or that partners will pay meaningful licence economics.
The next six to nine months are decisive and well defined. They are: the OECD 424/443 toxicology readouts, which are overdue against September guidance in public disclosures; conversion of the Japan term sheet into a binding supply and licence agreement with a late-2026 launch; and Asian vector-control efficacy data. Clean toxicology together with a signed Japan deal would materially re-rate the risk profile and improve the terms of the inevitable next raise. A toxicology setback or a lapsed Japan deal would likely force highly dilutive funding or a strategic rethink.
Position sizing should treat the September toxicology results, once disclosed, as the gating event, and the APVMA filing in Q2 CY2027 as the first real value inflection.
Sources consulted
-
Bio-Gene Technology Ltd, Appendix 4E and 2026 Annual Report (ASX, 28 Aug 2026)
-
Bio-Gene Technology Ltd, 2025 Annual Report (ASX, 25/26 Aug 2025)
-
Bio-Gene Technology Ltd, Half-Year Reports H1 FY2025 (27 Feb 2025) and H1 FY2026 (24 Feb 2026)
-
ASX announcements: 23 Feb 2023 (H1 FY2023), 26 Feb 2024 (H1 FY2024), 2 Sep 2024 (Rallis), 6 Sep 2024 (Investor Update), 13 Feb 2026 (OECD 424), 27 Apr 2026 (OECD 443), 3 Jun 2026 (Webinar), 24 Jun 2026 (SPP result)
-
InvestSMART announcement summaries (31 Oct 2025; 30 Jan, 24 Feb, 3 Mar, 31 Jul 2026)
-
Kalkine Media (31 Jul 2026); Smallcaps (Mar 2026); Grafa (Feb 2026)
-
StockAnalysis / S&P Global Market Intelligence (income statement, balance sheet, cash flow, quote as of 8 Oct 2026)
-
Market Index BGT company page (listing date, registry, substantial holders as of 20 Aug 2025)
-
Simply Wall St BGT ownership page (Nov 2025); Motley Fool AU BGT page; TipRanks (Alina Barlow substantial holding)
-
Rallis India / Tata Chemicals press release (2 Sep 2024)
-
annualreports.com and Stoxray company profiles; Pearler (IPO date and early price); Musaffa (Shariah screen)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Appointed | Prior roles | Education |
|---|---|---|---|---|
Alex Ding | Non-Executive Chair | NED 12 May 2023; Chair 1 Aug 2023 | 25+ years corporate lawyer; former partner at two leading Australian firms; M&A and capital markets; named in Best Lawyers in Australia | BComm, LLB (UNSW); LLM (USyd) |
Tim Grogan | Managing Director & CEO | 28 Aug 2023 | CEO, SIRA Pty Ltd (healthier sugar technologies); CEO, Dimerix BioScience (3 pharma partnering deals in 12 months); Starpharma (ASX:SPL), IPO and partnering | BLaw; BSc (Chemistry), University of Melbourne |
Peter May | Executive Director – R&D (0.9 FTE) | Director since 29 May 2015 | 20+ years in crop protection and pest management with Orica and Crop Care (now Nufarm); founded Xavca Pty Ltd (clients incl. Syngenta, Sorex/BASF); CEO then Chair of BioProspect Ltd (ASX:BPO) | BAppSc (Rural Tech)(Hons), UQ; MBA, QUT; GAICD |
Andrew Guthrie | Non-Executive Director; Chair, Audit & Risk | 26 Apr 2021 | 32 years at Syngenta and predecessors; Regional Director APAC; led the EAME business; member of Global Crop Protection Leadership team; retired 2019. Also NED of Terragen Holdings (ASX). | BAgSc (Hons); GAICD |
Chris Ramsey | Non-Executive Director; Chair, Remuneration & Nomination | 12 May 2023 | 30+ years in agriculture; leadership at Bayer, BASF, Nufarm/Crop Care; NED of North West Phosphate and Zondii; agribusiness consultant | BRurSc (Hons), UNE; GradDip Agribusiness, Monash |
Drew Speedy | CFO & Company Secretary (part-time consultant) | 1 Feb 2026 | Founder and Director, DTS Corporate; 20 years of CFO and company secretary roles | BBus (Acc); CPA; GAICD |
Edmond Tern | Former CFO & Company Secretary | Resigned 1 Feb 2026 | — | — |
Directors' Remuneration
| Name | Cash salary & fees | Cash STI | Superannuation | Equity (STI/LTI) | Total FY2026 | Total FY2025 |
|---|---|---|---|---|---|---|
Tim Grogan | 311,003 | 0 | 37,320 | 0 | 348,323 | 398,779 |
Peter May | 202,938 | 0 | 24,353 | 0 | 227,291 | 245,867 |
Alex Ding | 67,298 | 0 | 8,076 | 0 | 75,374 | 75,374 |
Andrew Guthrie | 53,367 | 0 | 6,404 | 0 | 59,771 | 59,771 |
Chris Ramsey | 46,429 | 0 | 5,571 | 0 | 52,000 | 52,000 |
Drew Speedy (from 1 Feb 2026) | 67,742 | 0 | 0 | 0 | 67,742 | — |
Edmond Tern (to 1 Feb 2026) | 75,425 | 0 | 7,071 | 0 | 82,496 | 142,941 |
Total KMP | 824,202 | 0 | 88,795 | 0 | 912,997 | 974,732 |
Major Shareholders
| Holder | Shares | Options | % of 438.06M shares |
|---|---|---|---|
Alex Ding (incl. Vana Belle Pty Ltd) | 34,122,081 | 21,739,130 | 7.8 |
Peter May | 2,259,597 | 317,392 | 0.5 |
Andrew Guthrie | 684,784 | 317,392 | 0.2 |
Drew Speedy | 600,000 | 300,000 | 0.1 |
Tim Grogan | 476,916 | 317,392 | 0.1 |
Chris Ramsey | 319,000 | 100,000 | 0.1 |
Total directors and CFO | 38,462,378 | — | about 8.8 |
Major Shareholders (Annual)
| Holder | Shares (Aug 2025) | % then | Note |
|---|---|---|---|
Dr Choon Huat Lee | 32,791,245 | 10.7 | Bought in the May 2025 placement |
Vana Belle Pty Ltd (Ding-associated) | 21,739,130+ | ~11.2 (Simply Wall St, Nov 2025) | Since increased to 34.1M total per AR |
Mark Chang | 21,109,174 | 6.9 | — |
Alina Barlow | 18,995,859 | 6.2 | Became substantial at 7.59% (12 May 2025) |
Citicorp Nominees Pty Ltd | 15,166,491 | 5.0 | Custodian |
T & L Ainsworth Investments | 6,683,185 | 2.2 | — |
Maclee Pty Ltd | 3,650,000 | 1.2 | — |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Positioning vs Bio-Gene |
|---|---|---|
Syngenta Group | Crop protection, public health (vector control) | Global discovery engine with novel-MoA insecticides; potential licensee |
Bayer Crop Science | Crop protection | Large pipeline; former parent of Envu |
BASF Agricultural Solutions | Crop, public health, grain storage | Former Flavocide grain collaborator |
Corteva Agriscience | Crop protection, biologicals | Spinosyn and natural-derived insecticides (direct analogue to "nature-derived" claim) |
FMC Corporation | Crop protection | Diamide franchise; biologicals |
Sumitomo Chemical | Household and public-health pyrethroids, vector control | Dominant in household insecticides in Japan; Sumitomo Corporation (separate trading house) is a Bio-Gene partner |
Envu | Professional pest and vector control | Current partner; also sells competing actives |
Nufarm (ASX: NUF) | Crop protection (off-patent) | Australian peer; generic pyrethroids |
Vestaron (private, US) | Peptide bio-insecticides, novel MoA | Closest "novel MoA biological" analogue |
Certis Biologicals / Mitsui | Biopesticides | Commercial botanical/microbial portfolio |
Marrone Bio (now Bioceres) | Biopesticides | Commercial biologicals |
Terragen Holdings (ASX: TGH) | Ag biologicals (ASX micro-cap) | Shares director Guthrie |
Clarke | Mosquito control | Partner and channel |
Peer Comparison FY2026
| Metric | Bio-Gene (FY2026) | FMC (2024) | Nufarm (FY2024) | Corteva (2024) |
|---|---|---|---|---|
Revenue | A$0 | ~US$4.2bn | ~A$3.3bn | ~US$16.9bn |
Revenue growth | n/m | Negative (destocking) | Negative | ~Flat |
Operating margin | n/m (loss A$2.36M) | Positive, high single/low double digit | Low single digit | Positive, low double digit |
R&D intensity | n/m (R&D A$1.77M) | ~7% of sales | Low (~2%) | ~8% of sales |
Recent Developments
--



